{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52","upperLimit":"79","value":"67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"description":"Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).\n\nconventional surgery: Some patients may undergo second-look surgery\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\nvincristine sulfate: Given IV\n\nradiation therapy: Undergo radiotherapy","id":"OG000","title":"Regimen II (Chemotherapy, Radiotherapy, Surgery)"}],"paramType":"NUMBER","populationDescription":"All eligible patients among this subset of regimen 2 patients were included in this outcome measure to regimen 2 patients (there were 16 patients determined ineligible). Patients found not to meet the eligibility requirements are by group policy not followed for adverse events or outcome measures.","reportingStatus":"POSTED","timeFrame":"From enrollment up to 5 years","title":"Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 2 Failure Free at 5 Years Following Study Entry","type":"PRIMARY","unitOfMeasure":"Estimated percentage of participants"}